Proactive Investors - Run By Investors For Investors

Mediclinic weak as first half profit falls due to a smaller contribution from its Swiss operation

Mediclinic’s chief executive Ronnie van der Merwe commented: "The poor performance in Switzerland more than outweighed the revenue growth and margin expansion delivered by the Southern Africa and the Middle East divisions"
Hospital
Mediclinic posted a pre-tax loss of £150mln in the first half, against a £10mln loss a year earlier, as revenue fell by 1.4% to £1.39bn

Mediclinic International Plc (LON:MDC) shares fell on Thursday as the firm saw its first-half profit decline due to a smaller contribution from its Swiss operation, Hirslanden.

The FTSE 250-listed private healthcare group saw its adjusted underlying earnings (EBITDA) fall by 8% to £213mln for the six months to September 30, down from £232mln a year earlier.

READ: Barclays has little confidence in the Mediclinic recovery story

The London and Johannesburg-quoted firm posted a pre-tax loss of £150mln in the first half, against a £10mln loss a year earlier, as revenue fell by 1.4% to £1.39bn from £1.41bn.

In Switzerland, the company’s adjusted EBITDA fell by 17% to SFr118mln despite revenue in the country rising by 1% to SFr826mln.

Mediclinic’s chief executive Ronnie van der Merwe commented: "The poor performance in Switzerland more than outweighed the revenue growth and margin expansion delivered by the Southern Africa and the Middle East divisions."

The group kept its interim dividend unchanged at 3.20p per share.

In early morning trading, Mediclinic shares were 3.9% lower at 341.40p.

In a separate announcement, Mediclinic also announced that its senior independent non-executive director Desmond Smith will retire from the board at the end of its annual general meeting expected to take place on 24 July 2019.

View full MDC profile View Profile

Mediclinic International Plc Timeline

Related Articles

An instrument made by Pressure BioSciences
June 26 2019
The company’s high-pressure technologies can help drug makers produce protein-based therapeutics, a market expected to touch $240 billion by 2023
microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
healthy gut
Mon
Here we take a look at AIM-listed life sciences group, OptiBiotix Health

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use